With "the Company" or "VibroSense" is meant VibroSense Dynamics AB (publ) with registration number 556669-2223. Amounts in parentheses in this report refer to the corresponding period of the previous year. The Company previously applied a broken financial year until the last Annual General Meeting, at which it was decided to change the Company's financial year from a broken fiscal year (1 July - 30 June) to a calendar year (1 January - 31 December). Therefore, the current financial year will cover a period of 18 months (6 quarters) and extend until 31 December 2025.

Fifth quarter (2025-07-01 to 2025-09-30)

• Net sales amounted to SEK 512,055 (431,801) and consist of revenues from sales and rentals of VibroSense Meter^® II instruments.
• Profit/loss after financial items amounted to SEK -1,109,318 (-1,210,287).
• Earnings per share* amounted to SEK -0.03 (-0.05).
• Equity ratio** amounted to 83.0 (86.7) %.

Fifteen months (2024-07-01 to 2025-09-30), comparative year 12 months (2023-07-01 to 2024-06-30)

• Net sales amounted to SEK 2,433,069 (2,131,974) and consist of revenues from sales and rentals of foot and hand instruments.
• Profit/loss after financial items amounted to SEK -5,958,634 (-7,668,669).
• Earnings per share* amounted to SEK -0.21 (-0.29).
• Equity ratio** amounted to 83.0 (86.7) %.

*Earnings per share: The period's result divided by the average number of shares. Average number of shares for the fifth quarter 2024/2025: 33,205,219 (26,074,395). Average number of shares during the twelve-month period from 1 October 2024 to 30 September 2025: 28,451,336 (26,660,490). Total number of shares in VibroSense as of 30 September 2025: 33,205,219 (26,074,395).

**Equity ratio: Shareholders' equity as a percentage of total assets.

Significant events during the period

• VibroSense Dynamics announces that Tarik Cengiz is stepping down from his position as CEO (2025-07-01)
• VibroSense obtains patent on biomarker to predict the risk of getting nerve damage during cancer treatment with chemotherapy (2025-08-01)
• Toni Speidel assumes the position of CEO (2025-09-01)
• VibroSense Dynamics strengthens its organization with three new employees, including a Key Account Manager in China (2025-09-08)

CEO Toni Speidel comments on the fifth quarter
Net sales for the fifth quarter of 2024/2025 amounted to SEK 512,055 (431,801) and consist of revenues from the sales and rentals of VibroSense Meter^® II instruments. The result for the fifth quarter of the 2024/2025 financial year amounted to SEK -1,109,318 (-1,210,287).

"With a strengthened organization, we are now increasing our efforts in marketing and sales within the EU and Asia."

Financial overview
During the quarter, we achieved higher sales compared with the same period last year, corresponding to an increase of approximately 18%. The result improved by about 7% as a result of reduced costs for conferences and consultancy services, as well as solid cost control.
We enter the end of the year with a stable cash position, providing good opportunities to finance our continued market activities.

Strengthened team
We have strengthened our marketing and sales team with three new employees, including a Key Account Manager in China. This addition is an important part of our broad launch of VibroSense Meter II in both the EU and Asia.

Stepping up marketing efforts
After receiving NMPA approval in China, we are now focusing on the final preparatory steps for the launch. We are making steady progress together with our partner UMCare although the process has taken longer than planned. However, our Key Account Manager in China has established good contact with UMCare's marketing and sales teams, creating a solid foundation for our entry into the Chinese market.
We are also intensifying our marketing activities in Europe, where we are working to identify new business opportunities and build long-term partnerships.

Updated sales strategy
With an updated sales strategy, we are now focusing on direct sales within the EU to end customers in the fields of Hand-Arm Vibration Syndrome (HAVS), diabetes, and oncology, instead of selling through distributors.
In Asia, however, the strategy is based on collaboration with distributors in Singapore, China, and Indonesia - markets with a high prevalence of diabetes, which is our main focus in the region.

Several research studies
In parallel, research studies are ongoing with various partners in the fields of diabetes and oncology in Sweden, Spain, the United Kingdom, and Ireland. We look forward to following the progress of these studies and expect additional studies to commence during the autumn.

Future outlook
The next and upcoming quarters will be affected negatively by a temporary loss of revenue due to the terminated agreement with the Occupational Healthcare company Avonova.  However, a potential increase in sales is expected if deliveries to China commence as planned.

CEO transition
During the quarter, Tarik Cengiz resigned from his assignment as CEO. I would like to extend my sincere thanks to Tarik for his valuable contributions and commitment to the company.
I have now resumed the role of CEO and look forward to leading VibroSense Dynamics through a very exciting phase. Finally, I would like to thank all shareholders and partners for your continued support and trust.

For more information, please contact:
Toni Speidel, CEO
VibroSense Dynamics AB (publ)
Phone: +46 40 88 026
Email: info@vibrosense.com
Website: www.vibrosense.com

"The new Gold Standard for reliable 
detection of nerve damage"

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers. 

Our vision that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.